A year later, biotech companies with cancer immunotherapies are beginning to reap the capital rewards of FDA's April 2010 approval of Dendreon's Provenge (sipuleucel-T) for prostate cancer.

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.